Rodríguez FZ, Jean-Louis B, Casaus PA, Joubert ÁG, Carulla DBM

Language: Spanish
References: 19
Page:
PDF size: 164.38 Kb.

ABSTRACT

An observational, descriptive and longitudinal study of 37 patients operated from colon cancer was made, with healing intention, in "Saturnino Lora Torres" Teaching Clinical Surgical Hospital in Santiago de Cuba, during the period 2006-2012 who presented tumorous recurrence diagnosed in the out-patient department, by means of an outline of postoperative follow up during a five year period or more, with the aim of identifying some factors associated to the survival. Among the main results of the series, it was obtained that the local-regional tumorous recurrence was predominant and the new surgery together with the adjuvant chemotherapy caused a greater survival in comparison to the one reached when using just chemical agents. On the other hand, most of the affected patients reached a survival no longer than one year, taking into account the interval from the diagnosis to death, and when concluding the study there was a mortality of 62,2%, whose most frequent cause was the tumorous recurrence itself. It could be concluded that surgeries were essentially palliative, although the diagnosis was in correspondence to the early detection during the period of postoperative follow up.

REFERENCES

1. American Cancer Society. Prevención y factores de riesgo del cáncer colorrectal. Atlanta: American Cancer Society; 2008.

2. Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, et al. National Comprehensive Cancer Network (NCCN) Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996; 10(11 Suppl): 140-75.

3. Mendoza Sánchez A, Sobrino Cossio S, Hernández Guerrero A, Córdova Pluma V, Alonso Lárraga O, Sánchez del Monte J. Utilidad de las escalas diagnósticas para cáncer de colon no polipósico hereditario en la población mexicana. Rev Gastroenterol Mex. 2005; 70(4): 411-5. MEDISAN 2014; 18(10):1393

4. Rodríguez Fernández Z, González-Rodiles Heredia RE, Casaus Prieto A. Cáncer de colon recurrente: intervalo libre de enfermedad y tratamiento adyuvante. MEDISAN 2009 [citado 12 May 2012]; 13(6).

5. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264(11): 1444-50.

6. Scheele J, Stangl R, Altendorf-Hofmann A. Indicators of prognosis after resection for colorectal secondaries. Surgery 1991; 110(1):13-29.

7. Wagman LD, Kemeny MM, Leong L. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 2000; 8(11): 1885-93.

8. Aranda Aguilar E. Tratamiento del cáncer de colon estadios II, III y IV. Oncología. 2004; 27(4): 258-61.

9. Gili M, Cabanillas JL, Bejar L. Mortalidad evitable y cáncer de colon y recto. Gac Sanit. 2007; 21(2): 176-8.

10. 10.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.

11. 11.Phillips RKS, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Local recurrence following “curative” surgery for large bowel cancer: II. The rectum and rectosigmoid. Br J Surg. 2009; 71(1): 17-20.

12. 12.McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg. 1992; 53(5): 780-5. 13.Solbiati L, Livraghi T, Goldberg SN, Hiérase T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001; 221(1): 159-66.

13. 14.Ravikumar TS. Interstitial therapies for liver tumors. Surg Oncol Clin N Am. 1996; 5(2): 365-77.

14. 15.González-Rodiles Heredia RE, Rodríguez Fernández Z, Casaus Prieto A. Cáncer de colon recurrente: diagnóstico y tratamiento. Rev Cubana Cir. 2009 [citado 8 Ene 2013]; 48(1).

15. 16.Rodríguez Fernández Z, González-Rodiles Heredia RE, Casaus Prieto A. Cáncer de colon recurrente: consideraciones actuales. Rev Cubana Cir. 2009 [citado 8 Ene 2010]; 48(1).

16. 17.Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229-37. MEDISAN 2014; 18(10):1394

17. 18.Rothenberg ML, Oza AM, Burger B, Berlin J, Marshall JL, Ramanathan RK, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol. 2003; 22: 252-1011.

18. 19.Colon and rectum. En: American Joint Committee on Cancer. AJCC Cancer Staging Atlas. New York: Springer; 2006. p. 107-17.

19. 20.Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994; 219(2): 174-82.